

SUPPLEMENTAL TABLE 1. Seroconversion rates, geometric mean titers, and geometric mean fold-rises following oral vaccination with a single standard-dose ($\geq 2 \times 10^8$ cfu) or high-dose ($\geq 2 \times 10^9$ cfu) of CVD 103-HgR live oral vaccine or two doses (14 days apart) of Shanchol inactivated cholera vaccine, using multiple imputation of missing values. Also shown are effect size comparisons between the different vaccines at different study days.

Days after vaccination	Seroconversion rate (≥ 4 -fold rise over baseline, percent)				Geometric mean titer (95% confidence interval)				Geometric mean fold-rise (GMFR, 95% confidence interval)			
	CVD 103-HgR		Shanchol		CVD 103-HgR		Shanchol		CVD 103-HgR		Shanchol	
	10 ⁸ cfu	10 ⁹ cfu	Post-1st dose	Post-2nd dose	10 ⁸ cfu	10 ⁹ cfu	Post-1st dose	Post-2nd dose	10 ⁸ cfu	10 ⁹ cfu	Post-1st dose	Post-2nd dose
0	-	-	-	-	28 ^a (21, 39)	28 ^b (21, 38)	47 ^c (32, 69)	-	-	-	-	-
7	53.6 ^d (38.4, 68.7)	61.8 ^e (47.1, 76.5)	39.8 ^f (25.5, 54.1)	-	118 ^g (56, 248)	208 ^h (99, 438)	113 ⁱ (67, 191)	-	4.1 ^{aa} (2.0, 8.6)	7.4 ^{bb} (3.6, 15.4)	2.4 ^{cc} (1.4, 4.0)	-
14	68.9 ^j (55.2, 82.6)	83.2 ^k (72.4, 94.1)	56.0 ^l (41.9, 70.1)	-	101 ^m (48, 216)	221 ⁿ (104, 471)	128 ^o (75, 218)	-	3.6 ^{dd} (1.6, 7.8)	7.9 ^{ee} (3.6, 17.4)	2.7 ^{ff} (1.6, 4.7)	-
21	75.4 ^p (62.6, 88.2)	86.6 ^q (76.4, 96.7)	-	68.5 ^r (55.2, 81.8)	83 ^s (41, 171)	179 ^t (87, 369)	-	140 ^u (84, 232)	2.9 ^{gg} (1.4, 6.2)	6.4 ^{hh} (3.0, 13.5)	-	3.0 ⁱⁱ (1.7, 5.0)
28	75.8 ^v (62.9, 88.6)	87.0 ^w (77.0, 96.9)	-	71.4 ^x (58.2, 84.6)	71 ^y (38, 132)	162 ^z (87, 301)	-	151 ^α (98, 234)	2.5 ^{jj} (1.4, 4.6)	5.8 ^{kk} (3.1, 10.6)	-	3.2 ^{ll} (2.1, 4.9)
	^d vs ^e , p=0.43; ^d vs ^f , p=0.19; ^e vs ^f , p=0.033; ^j vs ^k , p=0.10; ^j vs ^l , p=0.19; ^k vs ^l , p=0.003 ; ^p vs ^q , p=0.17; ^p vs ^r , p=0.45; ^q vs ^r , p=0.033 ; ^v vs ^w , p=0.17 ^v vs ^x , p=0.63; ^w vs ^x , p=0.060;				^a vs ^b , p=0.95 ^a vs ^c , p=0.045 ; ^b vs ^c , p=0.034 ; ^b vs ^c , p=0.034 ; ^g vs ^h , p=0.14; ^g vs ⁱ , p=0.92; ^h vs ⁱ , p=0.11; ^m vs ⁿ , p=0.046 ; ^m vs ^o , p=0.54; ⁿ vs ^o , p=0.16; ^s vs ^t , p=0.042 ; ^s vs ^u , p=0.16; ^t vs ^u , p=0.50; ^y vs ^z , p=0.010 ; ^y vs ^α , p=0.020 ; ^z vs ^α , p=0.84				^{aa} vs ^{bb} , p=0.12; ^{aa} vs ^{cc} , p=0.15; ^{bb} vs ^{cc} , p=0.003 ; ^{dd} vs ^{ee} , p=0.053; ^{dd} vs ^{ff} , p=0.50; ^{ee} vs ^{ff} , p=0.009 ^{gg} vs ^{hh} , p=0.045 ; ^{gg} vs ⁱⁱ , p=0.98; ^{hh} vs ⁱⁱ , p=0.045 ^{jj} vs ^{kk} , p=0.008 ; ^{jj} vs ^{ll} , p=0.44; ^{kk} vs ^{ll} , p=0.065			
Effect size at day 7 after vaccination (2-sided 95% CI)	Difference in seroconversion rates: ^e vs ^d : 8.3 (-12.5, 29.0) ^d vs ^f : 13.8 (-6.8, 34.3) ^e vs ^f : 22.0 (1.8, 42.3)				Ratio of GMTs: ^h vs ^g : 1.77 (0.71, 4.39) ^g vs ⁱ : 1.04 (0.50, 2.18) ^h vs ⁱ : 1.84 (0.88, 3.86)				Ratio of GMFRs: ^{bb} vs ^{aa} : 1.8 (0.7, 4.4) ^{aa} vs ^{cc} : 1.7 (0.8, 3.6) ^{bb} vs ^{cc} : 3.1 (1.5, 6.4)			
Effect size at day 14 after vaccination (2-sided 95% CI)	Difference in seroconversion rates: ^k vs ^j : 14.4 (-2.9, 31.6) ^j vs ^l : 12.9 (-6.6, 32.3) ^k vs ^l : 27.2 (9.7, 44.8)				Ratio of GMTs: ⁿ vs ^m : 2.19 (0.87, 5.52) ^m vs ^o : 0.79 (0.37, 1.68) ⁿ vs ^o : 1.73 (0.81, 3.68)				Ratio of GMFRs: ^{ee} vs ^{dd} : 2.2 (0.8, 5.9) ^{dd} vs ^{ff} : 1.3 (0.6, 2.9) ^{ee} vs ^{ff} : 2.9 (1.3, 6.4)			
Effect size at day 28 after vaccination (2-sided 95% CI)	Difference in seroconversion rates: ^w vs ^v : 11.2 (-4.8, 27.2) ^v vs ^x : 4.4 (-13.8, 22.6) ^w vs ^x : 15.6 (-0.6, 31.9)				Ratio of GMTs: ^z vs ^y : 2.27 (1.06, 4.85) ^y vs ^α : 0.47 (0.25, 0.88) ^z vs ^α : 1.07 (0.58, 1.99)				Ratio of GMFRs: ^{kk} vs ^{jj} : 2.3 (1.1, 4.9) ^{jj} vs ^{ll} : 0.8 (0.4, 1.4) ^{kk} vs ^{ll} : 1.8 (1.0, 3.3)			